Build

MOTS-C Deep Dive — The Mitochondrial 'Exercise in a Vial' Peptide

4 min read

MOTS-C Deep Dive — The Mitochondrial “Exercise in a Vial” Peptide

Provenance: educational study-synthesis (secondary source)

Mechanism-heavy review; no human data on exogenous MOTS-C and only one small human trial on its analog CB4211. MOTS-C is FDA category-2 (not compoundable) → the creator is not recommending its use. [educational]; research/educational use only. Source: YouTube — _b9Av7aTqas (Thorough structured capture; full verbatim not stored.)

Identity & mechanism

A 16-aa mitochondrial-derived peptide (encoded in the 12S rRNA region of mtDNA; humanin is the other mito-derived peptide) — vs SS-31, a mitochondrial-targeted synthetic. Production rises under metabolic stress (low glucose, oxidative stress, exercise, mito dysfunction). Actions: enters the nucleus → antioxidant response elements; modulates de novo purine biosynthesis + the folate cycle → intermediate buildup → activates AMPK → SIRT1 + PGC-1α → ↑mito function/biogenesis, glucose uptake, fat oxidation; inhibits NF-κB → ↓inflammation/oxidative. Net effect is mitohormesis (“come back stronger” after a stressor) — hence “exercise in a vial” (exercise itself raises MOTS-C).

Studied effects

  • Human: only CB4211 phase-1 (NAFLD, 11 pts, 25 mg SubQ daily ×4 wk) → −25% liver enzymes, −6% fasting glucose, no significant AEs.
  • Metabolic (mice): obese high-fat-diet mice −25% blood sugar, −20% body weight.
  • Longevity (mice): aging-model improvements (skin/liver/fat/metabolism); late-life dosing → strength/body-comp/movement + a +7% lifespan trend (NS). Plasma MOTS-C falls with age in humans.
  • Exercise (mice): single dose +12% run time / +15% distance; 10-day young mice +30–50% distance, all hit max sprint (vs 16% placebo); older mice ↑grip strength. Favors slow-twitch (endurance) fibers — a human genetic variant with less MOTS-C activity had more fast-twitch fibers / higher strength.
  • Muscle/bone: immobilized mice muscle loss 15%→5%; mild ↓bone loss (menopause model).
  • Neuro/CV (mice + human correlation): lower endogenous MOTS-C in Alzheimer’s & coronary-artery-disease patients; mouse models → improved cognition (Alzheimer’s), ↓brain damage (Parkinson’s), improved vessel function in vitro.

Risks (theoretical — mechanism-based)

  1. Folate depletion → ↑homocysteine (it modulates the folate cycle): measure homocysteine/folate before & after; methylated B vitamins on OFF (non-injection) days (B vitamins on injection days may blunt the effect); don’t repeat cycles if homocysteine climbs.
  2. Overstressing the mitochondria: chronic AMPK push → too catabolic vs mTOR (limits recovery/protein synthesis); electron-transport-chain overload → electron leak → oxidative stress. Mitigate with lab work, symptom monitoring (fatigue/strength/muscle loss), and nutrient support (Mg glycinate, CoQ10, alpha-lipoic acid, ±L-carnitine).
  3. Unknown (no human safety data): immune/cancer effects unstudied (mechanism argues against).
  • SubQ (oral ≈ 0 except advanced formulations). No PK data (half-life unknown) → dose conservatively. Lowest efficacious animal dose (0.5 mg/kg/day IP) → HED ≈ 3.33 mg/day → ~23 mg/week, but dose less frequently (mitohormesis + homocysteine recovery): 3×/week (the anti-aging study used 3×/wk in older mice). → ~7.5 mg 3×/wk; start 5 mg 3×/wk (anecdotal benefit). Timing: 30 min before aerobic exercise (synergy) and/or morning (circadian AMPK). Cycle: 4 weeks on / 4 weeks off (hormesis); use sparingly, not indefinitely.

Use-case verdict

Top-tier longevity (esp. mild insulin resistance / metabolic syndrome) — and the creator picks MOTS-C over SS-31 for longevity because it benefits mice of all ages (trains the mitochondria) vs SS-31’s structural support (older-mice benefit). Top-tier endurance/aerobic enhancement (but WADA-banned; don’t replace exercise — use synergistically). Pass for pure strength/power (slow-twitch shift). Useful for muscle maintenance during cutting.

CB4211 (the analog) & sourcing

CB4211 (CohBar) is a patented MOTS-C analog (structure undisclosed; likely ~1–2 aa changes + half-life/bioavailability tweaks; core mechanism intact). Until its structure is public, “CB4211” sold online is likely just minimally-modified MOTS-C. If CB4211 gains FDA approval it becomes a compoundable off-label option.

Candidate notes reinforced

  • CB4211 (MOTS-C analog), Humanin (the other mitochondrial-derived peptide); concept candidates: mitohormesis, homocysteine/folate cycle.

Graph View

Backlinks